Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (19)

2023

  1. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2021

  1. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  2. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

2020

  1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  2. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  5. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

2019

  1. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873

  2. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 5, pp. 1418-1429

  3. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018

    Allergy: European Journal of Allergy and Clinical Immunology

2018

  1. Corrigendum to “European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)” (Redox Biol. (2017) 13 (94–162)(S2213231717303373)(10.1016/j.redox.2017.05.007))

    Redox Biology

2017

  1. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

    Redox Biology, Vol. 13, pp. 94-162

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. CEND1 and NEUROGENIN2 Reprogram Mouse Astrocytes and Embryonic Fibroblasts to Induced Neural Precursors and Differentiated Neurons

    Stem Cell Reports, Vol. 5, Núm. 3, pp. 405-418

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544